Mar. 17 at 8:49 PM
$INDP 10-K filed
https://www.sec.gov/ix?doc=/Archives/edgar/data/1857044/000149315226010585/form10-k.htm
Some notes:
Looks like Decoy20 combo trial is done.
"As of the date of this Annual Report on Form 10-K, we have discontinued further enrollment in the Combination Study and there are no participants remaining in the study. We do not have any current plans to initiate a new clinical trial."
They plan to pursue a strategic transaction. They only report
$8.5M as of Dec 31, so I assume they will be looking at another reverse merger. Hwoever, they only expect cash to fund operations into Q2 of 2026.
